HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Capricor Therapeutics, maintaining a price target of $40. This suggests confidence in the company's future performance.
September 24, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Capricor Therapeutics, maintaining a $40 price target. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $40 price target by HC Wainwright & Co. indicates a positive outlook for Capricor Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100